Besides That Bristol, How Was the Show?

Let me join the masses in pointing out that Bristol-Myers Squibb's (NYSE: BMY  ) earnings suffered because of generic competition for its top-selling drug Plavix, that it markets with Sanofi. Sales of Plavix were down 60% year over year.

Okay? Can we move on now?

The joy of drug makers, especially large ones like Bristol, is that the large revenue declines are almost always foreseeable.  The drug went off patent; of course sales were going to decline.

It's Bristol's future that investors should be worried about and, for the most part, the prospects look pretty good. Excluding the declines of Plavix and Avapro/Avalide, which also saw a patent expiration in the last year, Bristol's sales increased 8%.

Cancer drugs Yervoy and Sprycel led the charge, with year-over-year increases of 71% and 26%, respectively. After a slow start, Onglyza and its related combo diabetes treatment, Kombiglyze, are picking up steam, with combined sales of $172 million, up 54% from the year ago period. That's nowhere near the level of Merck's (NYSE: MRK  ) Januvia franchise, the drugs' most direct competition, but they're decent sales, for sure.

Bristol sells the diabetes drugs with AstraZeneca (NYSE: AZN  ) . The addition of Amylin Pharmaceuticals' (Nasdaq: AMLN  ) drugs to the mix will not only lower the marketing costs to sell the medications but, by having more diabetes drugs in the sales rep's bag, it could actually accelerate sales, because they'll have more to talk to the doctors about.

Looking forward, Bristol has Eliquis, which it will market with Pfizer (NYSE: PFE  ) , assuming the companies can cross the t's and dot the i's to gain Food and Drug Administration approval. The blood thinner has blockbuster potential written all over it.

I think Bristol will be just fine after the media stops worrying about the sales decline of that drug. What was its name again?

Dividends can help investors ride the waves of slow drug development times. Check out the Fool's new free report "Secure Your Future With 9 Rock-Solid Dividend Stocks," where you'll find one drug developer and eight other promising companies. Just click here to get your free copy.

Fool contributor Brian Orelli holds no position in any company mentioned. Click here to see his holdings and a short bio. Motley Fool newsletter services have recommended buying shares of Pfizer. The Motley Fool has a disclosure policy. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. Try any of our Foolish newsletter services free for 30 days.


Read/Post Comments (0) | Recommend This Article (1)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

DocumentId: 1960877, ~/Articles/ArticleHandler.aspx, 7/26/2014 3:55:17 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement